Ritter A, Mellor R, Chalmers J, Sunderland M, Lancaster K. Key considerations in planning for substance use treatment: estimating treatment need and demand. J Stud Alcohol Suppl. 2019 Jan;Supp1 18:22-30. doi: 10.15288/jsads.2019.s18.22
Luckraz H, Manga N, Senanayake EL, Abdelaziz M, Gopal S, Charman SC, Giri R, Oppong R, Andronis L. Cost of treating ventilator-associated pneumonia post cardiac surgery in the National Health Service: results from a propensity-matched cohort study. J Intensive Care Soc. 2018 May;19(2):94-100. doi: 10.1177/1751143717740804
Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, Garcia-Albeniz X, Maurel J, Batlle JF. Clinical relevance of colorectal cancer molecular subtypes. Crit Rev Oncol Hematol. 2017 Jan;109:9-19. doi: 10.1016/j.critrevonc.2016.11.007
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.